◆ 会议时间：2025年11月13-16日
◆ 会议地点：捷克 布拉格

◆ 会议简介：

2025年第17届欧洲泌尿系统肿瘤多学科大会(EMUC2025)将于2025年11月13-16日在捷克布拉格举行，EMUC是欧洲最大的泌尿系统肿瘤学会议，由欧洲肿瘤内科学会（ESMO）、欧洲放射治疗与肿瘤学会（ESTRO）和欧洲泌尿外科协会（EAU）/欧洲泌尿外科学院（ESU）合作举办。为期四天的会议，来自欧洲以及欧洲以外其他国家众多的肿瘤学家、放射科医师、病理学家和泌尿科医师将分享他们的知识与经验，并对泌尿生殖系统肿瘤(GU)的最新研究进展进行认真评估和提出见解-领域国际医学会议网。EMUC至今已成举办十二届，现已建立了作为专业和科学交流领先平台宣的声誉，它不仅对有争议的问题进行批判性的审视，而且还对临床实践中的实际见解进行审视评估。无论是关于创新治疗的重要辩论，标准治疗的局限性还是新研究成果的影响，EMUC都是一次前沿的协作会议，旨在确定最佳疗法并解决临床实践中的空白。未经许可禁止复制摘录转载本站任何内容-国际医学会议网(lingyuint.com)

EMUC科学计划将包括预防、诊断和管理泌尿生殖系统（GU）癌症方面的当前相关进展，其范围将包括世界卫生组织对膀胱癌的最新分类、前列腺癌的现代成像、非肌层浸润性膀胱癌的综合系统治疗、主要试验的最新进展、该领域的最新分子发展等。在EMUC21上，还将解决当前存在的争议和挑战，例如优化利用诊断工具（包括分子标记物）以实现个性化治疗方法，为患者实现最大利益。

The 17th European Multidisciplinary Congress on Urological Cancers (EMUC25)

Date: 13-16 November 2025
Venue: Prague, Czech Republic

Organized by:
European Society for Medical Oncology (ESMO)
European Society for Radiotherapy and Oncology (ESTRO)
European Association of Urology (EAU)

下为上届信息

摘要征文投稿：

点此提交摘要>>>Submit Abstract>>>

Download the abstract submission rules here

Topics EMUC

Prostate Cancer, Localised – Basic Research & Trials
Prostate Cancer, Localised – Diagnosis
Prostate Cancer, Localised – Diagnosis, Pathology & Biopsies
Prostate Cancer, Localised – Treatment
Prostate Cancer, Localised – Follow up
Prostate Cancer, Localised – Follow up, Clinical / Prognosis
Prostate Cancer, Localised – Follow up, Quality of life / Patient reported outcomes
Prostate Cancer, Locally advanced – Basic Research & Trials
Prostate Cancer, Locally advanced – Diagnosis
Prostate Cancer, Locally advanced – Diagnosis, Pathology & Biopsies
Prostate Cancer, Locally advanced – Treatment
Prostate Cancer, Locally advanced – Follow up
Prostate Cancer, Locally advanced – Follow up, Clinical / Prognosis
Prostate Cancer, Locally advanced – Follow up, Quality of life / Patient reported outcomes
Prostate Cancer, Metastatic – Basic Research & Trials
Prostate Cancer, Metastatic – Diagnosis
Prostate Cancer, Metastatic – Diagnosis, Pathology & Biopsies
Prostate Cancer, Metastatic – Treatment
Prostate Cancer, Metastatic – Follow up
Prostate Cancer, Metastatic – Follow up, Clinical / Prognosis
Prostate Cancer, Metastatic – Follow up, Quality of life / Patient reported outcomes
Renal Tumour – Basic Research & Trials
Renal Tumour – Diagnosis
Renal Tumour – Treatment
Renal Tumour – Follow up, Clinical / Prognosis
Renal Tumour – Follow up
Renal Tumour – Follow up, Quality of life / Patient reported outcomes
Renal Tumour – Diagnosis, Pathology & Biopsies
Urothelial Cancer – Basic Research & Trials
Urothelial Cancer – Diagnosis
Urothelial Cancer – Diagnosis, Pathology & Biopsies
Urothelial Cancer – Treatment
Urothelial Cancer – Follow up
Urothelial Cancer – Follow up, Clinical / Prognosis
Urothelial Cancer – Follow up, Quality of life / Patient reported outcomes
Testicular Cancer – Diagnosis
Testicular Cancer – Treatment
Testicular Cancer – Follow up, Clinical / Prognosis
Testicular Cancer – Diagnosis, Pathology & Biopsies
Penile Cancer – Basic Research & Trials
Penile Cancer – Diagnosis
Penile Cancer – Diagnosis, Pathology & Biopsies
Penile Cancer – Treatment
Penile Cancer – Follow up
Penile Cancer – Follow up, Clinical / Prognosis
Penile Cancer – Follow up, Quality of life / Patient reported outcomes
Non-Disease specific

Topics ESUI

Prostate Cancer, Localised – Imaging
Prostate Cancer, Locally advanced – Imaging
Prostate Cancer, Metastatic – Imaging
Renal Tumour – Imaging
Urothelial Cancer – Imaging
Testicular Cancer – Imaging
Penile Cancer – Imaging

Publication

The accepted abstracts of EMUC24 are going to be published online in the EMUC resource centre, in the EMUC/ESUI app and as an online supplement by Elsevier on European Urology Open Science. If you do not want your case report(s) or video(s) published online please send an e-mail to emuc@congressconsultants.com.

Please note: Copyright of the abstract(s) is assigned to the EMUC office and any conflicts with any other scientific association will be the sole responsibility of the author(s).

注册费：

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。